Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: a Systematic Review
| Autor: | Konstantinos Kikiras, G. Geroulakos, Christiana Anastasiadou, George Galyfos, Gerasimos Papacharalampous, Anastasios Papapetrou, Ioannis Sachmpatzidis, Chrisostomos Maltezos, Naser Mohamed, Sotirios Giannakakis, Georgios Kastrisios |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Technical success MEDLINE 030204 cardiovascular system & hematology Cochrane Library Risk Assessment 030218 nuclear medicine & medical imaging 03 medical and health sciences Aortic aneurysm Blood Vessel Prosthesis Implantation 0302 clinical medicine Postoperative Complications Blood vessel prosthesis Risk Factors medicine Humans In patient Vascular Patency Aged Aortic aneurysm repair business.industry Endovascular Procedures General Medicine medicine.disease Surgery Blood Vessel Prosthesis Treatment Outcome Female Stents Cardiology and Cardiovascular Medicine business Abdominal surgery Aortic Aneurysm Abdominal |
| Zdroj: | Annals of vascular surgery. 63 |
| ISSN: | 1615-5947 |
| Popis: | Background This review aims to collect all available data on early and late outcomes in patients undergoing fenestrated endovascular aortic aneurysm repair (F-EVAR) for pararenal or juxtarenal abdominal aortic aneurysms (AAAs). Methods The Pubmed, Embase, Scopus and Cochrane Library databases were systematically searched to identify eligible studies. Studies reporting at least early mortality after F-EVAR in patients with pararenal or juxtarenal AAA were included. Thirty-day outcomes were defined as early, and outcomes reported after 30 days postoperatively were defined as late. Basic characteristics of all studies and demographics of patients were reported. Results Overall, 30 studies (17 retrospective and 13 prospective) including 23,385 patients in total were included. Out of 23,385 patients, a total of 2,271 patients were treated with F-EVAR for pararenal/juxtarenal AAA. Overall, 4,216 target vessels were to be treated (data from 24 studies). Pooled early mortality reached 2.55% (ranging from 0% to 6.74%), with a pooled technical success of 96.8% (ranging from 82.8% to 100%). Regarding late outcomes, pooled all-cause mortality reached 17% (ranging from 0% to 50%), 1-year primary patency was 94.6% (ranging from 91.8% to 97.1%) and reintervention rate was 10.4% (ranging from 0% to 57.4%). Mean/median follow-up ranged from 3 to 60 months. Conclusions Early outcomes indicate that F-EVAR is a safe and efficient treatment for patients with pararenal/juxtarenal AAAs. Although long-term outcomes are acceptable, late-intervention rate remains high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|